CANCER:

Pancreatic Adenocarcinoma

Related cancers:

‹

Pancreatic Cancer (300)

Pancreatic Ductal Adenocarcinoma (69)

Pancreatic Cancer (300)

Pancreatic Ductal Adenocarcinoma (69)

›

No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	LV5FU2 Sensitive: A2 - Guideline	LV5FU2 Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	CAPOX Sensitive: A2 - Guideline	CAPOX Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	NTRK3 fusion NTRK3 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	NTRK2 fusion NTRK2 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline	larotrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	NTRK3 fusion NTRK3 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	erlotinib Sensitive: A2 - Guideline	erlotinib Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	capecitabine Sensitive: A2 - Guideline	capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	5-fluorouracil + capecitabine Sensitive: A2 - Guideline	5-fluorouracil + capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	5-fluorouracil Sensitive: A2 - Guideline	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine Sensitive: A2 - Guideline	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine + capecitabine Sensitive: A2 - Guideline	gemcitabine + capecitabine Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	BRCA1 mutation BRCA1 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline	cisplatin + gemcitabine Sensitive: A2 - Guideline
BRCA2 mutation BRCA2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	BRCA2 mutation BRCA2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline	cisplatin + gemcitabine Sensitive: A2 - Guideline
PALB2 mutation PALB2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	PALB2 mutation PALB2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline	cisplatin + gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	No biomarker No biomarker	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	5-fluorouracil + irinotecan Sensitive: A2 - Guideline	5-fluorouracil + irinotecan Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	NTRK1 fusion NTRK1 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	MSI-H/dMMR MSI-H/dMMR	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	NTRK2 fusion NTRK2 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	entrectinib Sensitive: A2 - Guideline	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	NTRK1 fusion NTRK1 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	larotrectinib Sensitive: C1 - Off-label	larotrectinib Sensitive: C1 - Off-label
RET fusion RET fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	RET fusion RET fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	pralsetinib Sensitive: C1 - Off-label	pralsetinib Sensitive: C1 - Off-label
TMB-H TMB-H	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	TMB-H TMB-H	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
KRAS G12R KRAS G12R	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	KRAS G12R KRAS G12R	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	selumetinib Sensitive: C3 – Early Trials	selumetinib Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	KRAS mutation KRAS mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	trametinib Sensitive: C3 – Early Trials	trametinib Sensitive: C3 – Early Trials
HER-2 expression HER-2 expression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	HER-2 expression HER-2 expression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	trastuzumab + erlotinib + gemcitabine Sensitive: C3 – Early Trials	trastuzumab + erlotinib + gemcitabine Sensitive: C3 – Early Trials
EGFR expression EGFR expression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	EGFR expression EGFR expression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	trastuzumab + erlotinib Sensitive: C3 – Early Trials	trastuzumab + erlotinib Sensitive: C3 – Early Trials
CDH1 expression CDH1 expression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	CDH1 expression CDH1 expression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	erlotinib + selumetinib Sensitive: C3 – Early Trials	erlotinib + selumetinib Sensitive: C3 – Early Trials
SMAD4 deletion SMAD4 deletion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	SMAD4 deletion SMAD4 deletion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials	gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	TP53 mutation TP53 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	BRCA2 mutation BRCA2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials	FOLFIRINOX Sensitive: C3 – Early Trials
TP53 mutation TP53 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	TP53 mutation TP53 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	FOLFOX Sensitive: C3 – Early Trials	FOLFOX Sensitive: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	BRCA2 mutation BRCA2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	FOLFOX Sensitive: C3 – Early Trials	FOLFOX Sensitive: C3 – Early Trials
SEL1L-NTRK1 fusion SEL1L-NTRK1 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	SEL1L-NTRK1 fusion SEL1L-NTRK1 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	larotrectinib Sensitive: C4 – Case Studies	larotrectinib Sensitive: C4 – Case Studies
SEL1L-NTRK1 fusion SEL1L-NTRK1 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	SEL1L-NTRK1 fusion SEL1L-NTRK1 fusion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Resistant: C4 – Case Studies	gemcitabine + albumin-bound paclitaxel Resistant: C4 – Case Studies
PD-L1 expression + TMB-H + FANCA deletion PD-L1 expression + TMB-H + FANCA deletion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	PD-L1 expression + TMB-H + FANCA deletion PD-L1 expression + TMB-H + FANCA deletion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	toripalimab Sensitive: C4 – Case Studies	toripalimab Sensitive: C4 – Case Studies
PD-L1 expression + TMB-H + FANCA deletion PD-L1 expression + TMB-H + FANCA deletion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	PD-L1 expression + TMB-H + FANCA deletion PD-L1 expression + TMB-H + FANCA deletion	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: C4 – Case Studies	gemcitabine + albumin-bound paclitaxel Sensitive: C4 – Case Studies
EGFR exon 19 mutation EGFR exon 19 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	EGFR exon 19 mutation EGFR exon 19 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	erlotinib Sensitive: C4 – Case Studies	erlotinib Sensitive: C4 – Case Studies
BRCA2 mutation + CHEK2 mutation BRCA2 mutation + CHEK2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	BRCA2 mutation + CHEK2 mutation BRCA2 mutation + CHEK2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	FOLFIRINOX Sensitive: C4 – Case Studies	FOLFIRINOX Sensitive: C4 – Case Studies
BRCA2 1153insT BRCA2 1153insT	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	BRCA2 1153insT BRCA2 1153insT	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: C4 – Case Studies	cisplatin + gemcitabine Sensitive: C4 – Case Studies
KRAS mutation KRAS mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	KRAS mutation KRAS mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cobimetinib Sensitive: D – Preclinical	cobimetinib Sensitive: D – Preclinical
FAM83D overexpression FAM83D overexpression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	FAM83D overexpression FAM83D overexpression	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	gemcitabine Resistant: D – Preclinical	gemcitabine Resistant: D – Preclinical
PTGR1 elevation + HRD PTGR1 elevation + HRD	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	PTGR1 elevation + HRD PTGR1 elevation + HRD	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	LP-184 Sensitive: D – Preclinical	LP-184 Sensitive: D – Preclinical
KRAS G13D KRAS G13D	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	KRAS G13D KRAS G13D	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	ASN007 Sensitive: D – Preclinical	ASN007 Sensitive: D – Preclinical
KRAS G12C KRAS G12C	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	KRAS G12C KRAS G12C	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	ASN007 Sensitive: D – Preclinical	ASN007 Sensitive: D – Preclinical

Pancreatic Adenocarcinoma

Associations(45)

Associations
(45)